Dosage and administration
One bottle of Semax contains 60 drops, each having 50 mcg of the active ingredient. The average dose is 2-3 drops in each nostril. If there is a need to take more, a 15-minute interval should be taken between the administrations. Semax should be taken up to 3 times per day.
With the purpose of cognitive improvement, Semax should be taken once a day - 2 drops in each nostril - for a period of 3 to 14 days.
Depending on the chosen dosage, one bottle is sufficient for a course of 3 - 10 days.
Extremely rare individual allergic reactions.
Keep in a dark place at a temperature less than 10 C (50 F) for up to two years.
Note: As peptides, Semax and Selank should not be exposed to high temperatures for long periods of time. They can however be safely kept at the room temperature for period of less than a month. Each bottle also contains methylparaben (0.1%), which works as a preservative.
Country of Manufacture: Russia
Semax is a Russian nootropic drug that is used in nasal spray and nasal drops form to improve cognitive functions and treat various medical conditions. By its structure, Semax is a fragment of endogenous neuropeptide ACTH.
The positive effects of neuropeptides were discovered in the late 1960s when D. de Vid - who coined the term neuropeptide - conducted a number of trials on white rats and found that fragments of adrenocorticotropic hormones facilitate learning abilities.
It was not, however, until the late 1970s, when the Soviet Ministry of Defence commissioned a wide range of experiments to determine the optimal way to prolong the effects and increase their scope.
After a long and complicated trial and error process, the optimal peptide formula was synthesized, and it had 50 times longer effects than its natural analogue.
After that, an extensive research on humans was started to ensure safety, increase efficiency and determine the optimal dosages and delivery methods. As a result, on 20 December 1994, Semax was officially brought to market. Since then it won a number of international awards and, on 7 December 2011, was included in the List of Vital & Essential Drugs, as studies showed that it was one of the most important remedies after strokes.
Primary uses of Semax 0.1%:
- Increasing attention during repetitive and monotonous tasks;
- Increasing intellectual capacity in extreme circumstances;
- Alleviating the effects of cerebrovascular diseases;
Primary uses of Semax 1%:
- Faster recovery after strokes;
- Alleviation of migraines;
- Transient ischemic attacks;
Is Semax going to be degraded after a long journey from Russia to the US?
In short, No.
Semax is a pharmaceutical nootropic produced by Peptogen Inc. According to the official instruction (drug sheet), once opened a bottle of Semax is to be kept at temperatures below 30°C (86°F) for a period of up to 30 days. Apart from that, we want to stress some other points:
- The product contains methylparaben (0.01%), which works as a preservative and ensures longer shelf-life. It is completely safe and frequently used in other supplements.
- The product is sterile and produced on a GMP-compliant factory, which is likely to increase storage duration.
- For longer periods of time, Semax should be stored at temperatures below 10°C (50°F). The shelf life of a new product is 2 years if stored below 10°C (50°F).
- This implies that if the temperature between 10°C (50°F) to 30°C (86°F) the storage duration is anywhere between 30 days to 2 years, depending on the temperature.
*So far, nobody has complained about Semax being unusable, though we have been shipping for more than two years now.
Country of Manufacture: Russia
Availability: in stock
- Asmarin et al (1997) A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study https://www.ncbi.nlm.nih.gov/pubmed/9173745
- Miasoedova et al (1999) Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/10358912
- Gusev et al (2005) Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency https://www.ncbi.nlm.nih.gov/pubmed/15792140
- Eremin et al (2005) Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents https://www.ncbi.nlm.nih.gov/pubmed/16362768 Dolotov et al (2006) Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus https://www.ncbi.nlm.nih.gov/pubmed/16996037
- SJ Tsai (2007) Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome https://www.ncbi.nlm.nih.gov/pubmed/16996699
- Agapova et al (2008) Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex https://www.ncbi.nlm.nih.gov/pubmed/18756821
- Grivennikov et al (2008) Effects of behaviorally active ACTH (4-10) analogue - Semax on rat basal forebrain cholinergic neurons https://www.ncbi.nlm.nih.gov/pubmed/18431004
- Shadrina et al (2010) Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action https://www.ncbi.nlm.nih.gov/pubmed/19662538
- Manchenko et al (2010) Nootropic and analgesic effects of Semax following different routes of administration https://www.ncbi.nlm.nih.gov/pubmed/21268834
- Medvedeva et al (2014) The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987924/
- Shypshyna et al (2015) Effect of peptide semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons https://www.ncbi.nlm.nih.gov/pubmed/26552305
- Medvedeva et al (2017) Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats https://www.ncbi.nlm.nih.gov/pubmed/28255762
- Gusev et al (2018) The efficacy of semax in the tretament of patients at different stages of ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/29798983
- Lebedeva et al (2018) Effects of Semax on the Default Mode Network of the Brain https://www.ncbi.nlm.nih.gov/pubmed/30225715